Om Megashree Pharmaceuticals IPO result will be published tomorrow 12th Chaitra, 2081 (Tuesday). The allotment process will be held at the premises of the issue manager, Prabhu Capital Limited, in Lazimpat, Kathmandu. This is the second phase of IPO for the general public in Nepal before this the first phase of its IPO distribution was opened for the Nepalese working abroad. The IPO price per unit is set at Rs. 100 per share.
IPO Allocation Breakdown
- Total Issued Capital: Rs. 60 Crores.
- Public Issue: 30% (18,00,000 units worth Rs. 18 Crores).
- Nepalese Citizens Working Abroad: 10% (1,80,000 units).
- Mutual Funds: 5% (90,000 units).
- Company Employees: 3% (54,000 units).
- General Public: 14,76,000 units.
Key Highlights of the IPO Allotment
CARE Ratings Nepal’s Reaffirmation
CARE Ratings Nepal Limited (CRNL) has reaffirmed the following ratings for OMPL:
- Issuer Rating: ‘CARE-NP BB- (Is)’ – indicating a moderate risk of default in meeting financial obligations.
- Long-term Bank Facilities: ‘CARE-NP BB-’.
- Short-term Bank Facilities: ‘CARE-NP A4’.
These ratings reflect the company’s financial stability and operational capabilities.
About Om Megashree Pharmaceuticals Limited
Om Megashree Pharmaceuticals is a Public Company established on June 12, 2016. Engaged in manufacturing pharmaceutical products at our plant in Jugedi, Chitwan. With partial operations starting on February 19, 2024, our head office is located in New Baneshwor, Kathmandu. We aim to become a global name in pharmaceuticals by delivering high-quality, innovative, and affordable medicines, guided by our core values of integrity, innovation, quality, collaboration, growth, and unity.
